Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology

放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送

基本信息

项目摘要

PROJECT SUMMARY / ABSTRACT Although survival rates for children diagnosed with a primary malignant brain tumor have improved, radiation induced damage to the developing nervous system remains a significant problem. Few treatment options are available once malignant cells have metastasized to the leptomeninges that surround the brain and spinal cord. Leptomeningeal metastasis (LM) cannot be surgically resected, and systemic chemotherapy is hindered by the presence of the blood-brain and blood-spinal cord barriers, leaving high dose craniospinal radiation as the only effective treatment option. Some investigators have administered therapeutics directly into the intrathecal space with the hope that locally administered drugs will better reach LM. However, action of intrathecally administered agents is limited by rapid clearance and inadequate tissue penetration as cerebrospinal fluid (CSF) turns over. Furthermore, most traditional chemotherapeutics are poorly water soluble and cannot be administered to the CSF at relevant concentrations. We have recently developed a novel approach for encapsulating the histone deacetyle inhibitor (HDACI) quisinostat within biodegradable and biocompatible NPs (QNPs). Our preliminary data demonstrate that intrathecally administered NPs distribute readily across the surfaces of the brain and spinal cord, are well retained within the subarachnoid space, and localize with lesions to slow the growth of LM in a murine model of metastatic medulloblastoma. Here, we propose a comprehensive approach for optimizing the design of radiation sensitizing NPs for intrathecal drug delivery to treat LM. These NPs serve not just as a stationary depot to prolong drug presence in the central nervous system but as mobile carriers that we predict will selectively sensitize metastatic lesions to radiation. We will, (1) engineer the surface of NPs to further improve their localization with LM, (2), determine the relationship between drug delivery and efficacy in models of medulloblastoma, and, (3), establish species scaling of direct-to-CSF nanoparticle delivery. Treatments will be evaluated in patient derived and genetically engineered models of medulloblastoma exhibiting LM. Fluorescent barcoding, matrix assisted laser desorption ionization (MALDI), and positron emission tomography (PET) imaging approaches will be used to precisely localize NP and drug delivery to LM with quantitative, cellular-level resolution. By directly pairing multiple measures of delivery, activity, and efficacy, we expect to develop a comprehensive understanding of barriers to effective drug delivery within the subarachnoid space. Most importantly, these studies will advance new nanotechnology toward the clinic for better treatment of pediatric brain tumors.
项目摘要/摘要

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial.
将 5-氮杂胞苷 (5-AZA) 输注到患有复发性后窝室管膜瘤的儿童的第四脑室或切除腔中:一项试点临床试验。
  • DOI:
    10.1007/s11060-018-03055-1
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Sandberg,DavidI;Yu,Bangning;Patel,Rajan;Hagan,John;Miesner,Emilie;Sabin,Jennifer;Smith,Sarah;Fletcher,Stephen;Shah,ManishN;Sirianni,RachaelW;Taylor,MichaelD
  • 通讯作者:
    Taylor,MichaelD
High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model.
  • DOI:
    10.3171/2020.2.peds19786
  • 发表时间:
    2020-08-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sandberg DI;Kharas N;Yu B;Janssen CF;Trimble A;Ballester LY;Patel R;Mohammad AS;Elmquist WF;Sirianni RW
  • 通讯作者:
    Sirianni RW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rachael W Sirianni其他文献

Rachael W Sirianni的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rachael W Sirianni', 18)}}的其他基金

Exploiting sex-dependent brain injury response for nanoparticle therapeutics
利用性别依赖性脑损伤反应进行纳米颗粒治疗
  • 批准号:
    10320959
  • 财政年份:
    2021
  • 资助金额:
    $ 71.15万
  • 项目类别:
Exploiting sex-dependent brain injury response for nanoparticle therapeutics
利用性别依赖性脑损伤反应进行纳米颗粒治疗
  • 批准号:
    10532166
  • 财政年份:
    2021
  • 资助金额:
    $ 71.15万
  • 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
  • 批准号:
    9811126
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:
Targeting leptomeningeal metastasis in medulloblastoma
靶向髓母细胞瘤的软脑膜转移
  • 批准号:
    9917838
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
  • 批准号:
    10200874
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:
Targeting Leptomeningeal Metastasis in Medulloblastoma
靶向髓母细胞瘤的软脑膜转移
  • 批准号:
    10829143
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:
Intrathecal delivery of radiation sensitizing nanoparticles in pediatric neuro-oncology
放射增敏纳米颗粒在儿科神经肿瘤学中的鞘内递送
  • 批准号:
    10755398
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:
Targeting leptomeningeal metastasis in medulloblastoma
靶向髓母细胞瘤的软脑膜转移
  • 批准号:
    10595323
  • 财政年份:
    2019
  • 资助金额:
    $ 71.15万
  • 项目类别:

相似国自然基金

膀胱癌细胞通过调控淋巴内皮细胞angiopoietin-2修饰促进淋巴转移的分子机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    54.7 万元
  • 项目类别:
    面上项目
中药单体蟾毒灵调控Angiopoietin-2蛋白分泌抑制肝癌血管生成的分子机制研究
  • 批准号:
    81603348
  • 批准年份:
    2016
  • 资助金额:
    17.0 万元
  • 项目类别:
    青年科学基金项目
肿瘤包绕型血管关键分子Angiopoietin-2在肝癌的表达调控机制及其功能
  • 批准号:
    81602151
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
炎症与淋巴管再生: Angiopoietin-2的调控作用
  • 批准号:
    30772262
  • 批准年份:
    2007
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
血管生成素2/Tie2信号对胰腺神经内分泌肿瘤肝转移的调控
  • 批准号:
    10746299
  • 财政年份:
    2023
  • 资助金额:
    $ 71.15万
  • 项目类别:
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations
血管生成素 2 信号传导靶向治疗动静脉畸形
  • 批准号:
    10420883
  • 财政年份:
    2022
  • 资助金额:
    $ 71.15万
  • 项目类别:
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
血管生成素2/Tie2信号对胰腺神经内分泌肿瘤肝转移的调控
  • 批准号:
    10521805
  • 财政年份:
    2022
  • 资助金额:
    $ 71.15万
  • 项目类别:
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
血管生成素2/Tie2信号对胰腺神经内分泌肿瘤肝转移的调控
  • 批准号:
    10663955
  • 财政年份:
    2022
  • 资助金额:
    $ 71.15万
  • 项目类别:
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
血管生成素2/Tie2信号对胰腺神经内分泌肿瘤肝转移的调控
  • 批准号:
    10932452
  • 财政年份:
    2022
  • 资助金额:
    $ 71.15万
  • 项目类别:
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations
血管生成素 2 信号传导靶向治疗动静脉畸形
  • 批准号:
    10586049
  • 财政年份:
    2022
  • 资助金额:
    $ 71.15万
  • 项目类别:
Mechanisms driving endothelial angiopoietin-2 expression and vascular dysfunction during pediatric sepsis
小儿脓毒症期间内皮血管生成素 2 表达和血管功能障碍的驱动机制
  • 批准号:
    10684768
  • 财政年份:
    2021
  • 资助金额:
    $ 71.15万
  • 项目类别:
Mechanisms driving endothelial angiopoietin-2 expression and vascular dysfunction during pediatric sepsis
小儿脓毒症期间内皮血管生成素 2 表达和血管功能障碍的驱动机制
  • 批准号:
    10347958
  • 财政年份:
    2021
  • 资助金额:
    $ 71.15万
  • 项目类别:
IDENTIFICATION OF A NOVEL ANGIOPOIETIN 2 SIGNALLING CENTRE IN THE EMBRYONIC HAEMATOPOIETIC STEM CELL NICHE
胚胎造血干细胞生态位中新型血管生成素 2 信号中心的鉴定
  • 批准号:
    MR/R018081/1
  • 财政年份:
    2018
  • 资助金额:
    $ 71.15万
  • 项目类别:
    Research Grant
The role of angiopoietin-2 in anaphylactic shock
血管生成素2在过敏性休克中的作用
  • 批准号:
    16K11428
  • 财政年份:
    2016
  • 资助金额:
    $ 71.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了